WPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

HOUSTON, Feb. 18, 2021 /PRNewswire/ — WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) (“WPD”) and CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD Pharmaceuticals received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland for its planned upcoming Berubicin clinical trial in adults with Glioblastoma Muliforme (GBM) under the WPD-201 Clinical Trial Protocol. CNS Pharmaceuticals has received study level Central IRB Approval from the Central IRB for the CNS-201 Clinical Trial Protocol.

The release as fetched from its publisher. cnspharma.com ↗